Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections

Clicks: 312
ID: 6124
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #536 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections Nobuaki Shime,1,2 Nobuyuki Saito,3 Miya Bokui,4 Naoki Sakane,5 Mitsuhiro Kamimura,6 Tsutomu Shinohara,7 Tadashi Kosaka,8 Hisashi Ishikura,9 Atsuko Kobayashi,10 1Department of Emergency and Critical Care Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan; 2Department of Emergency and Critical Care Medicine, Kyoto Medical Centre, Kyoto, Japan; 3Shock and Trauma Center, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan; 4Department of Pharmacy, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan; 5Clinical Research Institute, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan; 6Department of Pulmonology, National Hospital Organization Disaster Medical Centre, Tokyo, Japan; 7Department of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi, Japan; 8Department of Pharmacy, Kyoto Prefectural University, School of Medicine, Kyoto, Japan; 9Department of Surgery, Tokushima Red Cross Hospital, Komatsushima, Japan; 10Department of Central Laboratory, Takarazuka City Hospital, Hyogo, Japan Objective: To evaluate the clinical outcomes associated with anti-methicillin-resistant Staphylococcus aureus (MRSA) antimicrobials. Methods: We reviewed a prospective database of 247 consecutive patients with clinically and microbiologically confirmed MRSA infections, hospitalized in 7 Japanese hospitals between April 2014 and March 2015, and treated with anti-MRSA pharmaceuticals. Survival was measured at 30 days. We examined the relationships between initial antimicrobial administered and survival and organ toxicity. HR and 95% CIs were calculated. Results: Overall 30-day mortality was 12%. The lungs were infected in 105 (41%), skin and soft tissue in 73 (30%), and bones and joints in 21 (9%) patients. Bacteremia complicated the illness in 69 patients (28%). Among 5 pharmaceuticals, vancomycin was prescribed to 174 (71%), linezolid to 38 (16%), teicoplanin to 22 (9%), and daptomycin to 11 (5%) patients. Vancomycin tended to be associated with the lowest survival (HR
Reference Key
nobuaki2018clinicalinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nobuaki Shime;Nobuyuki Saito;Miya Bokui;Naoki Sakane;Mitsuhiro Kamimura;Tsutomu Shinohara;Tadashi Kosaka;Hisashi Ishikura;Atsuko Kobayashi and
Journal Infection and drug resistance
Year 2018
DOI
10.2147/IDR.S159447
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.